Inhaled pulmonary vasodilators in severe COVID-19: Don't hold your breath

[...]hypoxia-induced pulmonary vasoconstriction and the use of non-selective vasopressors may increase pulmonary vascular resistance leading to greater pulmonary hypertension and worsened right ventricular function. Residual confounding of the study design limits any conclusions as to the benefit of iEpo administration early in the disease course of COVID-19. Because there was no control group, it is not possible to determine whether iEpo administration influenced intubation rates. [...]the results of the 3 studies published in the Journal may stimulate discussion at the bedside of the potential benefits of pulmonary vasodilators in severe COVID-19 but are unlikely to change current practice.